The efficacy of CDK4/6 inhibitors in the treatment of HR+/HER2− breast cancer demonstrates the success of applying basic knowledge of cell cycle regulation to the generation of clinically relevant drugs. This evidence concerns the gene CDK4 and breast carcinoma.